SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...

(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, Inc. announced Thursday an agreement designed to enhance ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...

Genetic testing has the potential to transform patient care. The potential of precision medicine lies in the possibility that insights from our genetic code may hold the key to preventing disease, ...

SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...

Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45 Myriad Genetics, Inc. (NASDAQ: ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the ...